Dapagliflozin DECLAREd safe

Dapagliflozin

Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers Squibb and AstraZeneca. It is currently undergoing phase III development worldwide with regulatory submissions expected in the second half of 2010. This review looks at the development history and scientific profile of this drug to date.

Australia declared polio free.

For Australia to be declared polio free, evidence of the absence of circulation of wild poliovirus was required by the Regional Commission for the Certification of Eradication of Poliomyelitis in the Western Pacific in August 2000. Data on surveillance of poliomyelitis, acute flaccid paralysis (AFP), vaccine associated paralytic polio and enteroviruses were provided to document the absence of c...

Handling Declared Information Leakage

We address the problem of controlling information leakage in a concurrent declarative programming setting. Our aim is to define formal tools in order to distinguish between authorized, or declared, information flows such as password testing (e.g., ATM, login processes, etc.) and non-authorized ones. We propose to define security policies as rewriting systems. Such policies define how the privac...

Non-fulfillment of the Declared Inflation Target

Dapagliflozin-Induced Acute-on-Chronic Liver Injury

Sodium-glucose cotransporter 2 inhibitors are a new class of oral hypoglycemic agents, and thus safety data are limited. We present a 48-year-old woman with type 2 diabetes mellitus and Child's Class A cirrhosis secondary to nonalcoholic steatohepatitis presenting with jaundice and acute cholestatic liver injury. Other than starting dapagliflozin, she reported no medication changes or supplemen...